Perfluorodecanoic acid (PFDA) exposure, through stabilizing HIF-1α to induce VEGF/VEGFR2 autocrine signaling, promotes colorectal cancer cell proliferation

Perfluorodecanoic acid (PFDA) is a persistent organic pollutant widely present in the environment and resistant todegradation. In recent years, due to its extensive use in industrial production and consumer products, PFDA continuously accumulates in organisms and has become a global public health concern. Although epidemiological data suggest a possible association between PFDA and various cancer risks, its specific carcinogenic mechanism, particularly in colorectal cancer development, remains unclear. Therefore, this study aims to investigate the effects of environmentally relevant concentrations of PFDA on the biological behavior of colorectal cancer cells and to elucidate. the underlying molecular mechanisms. In vitro, human colorectal cancer cell lines HCT116 and HT-29 were used as models. Our results demonstrated that PFDA treatment significantly enhanced the malignant phenotype of cancer cells in a dose-dependent manner. Colony formation ability was enhanced. Meanwhile, cell invasion capacity was also significantly improved. Additionally, PFDA exposure induced glycolytic metabolic reprogramming in cancer cells, a metabolic feature closely associated with rapid tumor growth and malignant progression. To further elucidate the mechanism, our team conducted in-depth molecular biological investigations. The study found that PFDA does not affect gene transcription but instead directly binds to and stabilizes the VHL protein, preventing its degradation of HIF-1α. This consequently significantly upregulates its classic downstream target genes, VEGF and its receptor VEGFR2, thereby activating key downstream pro-survival and proliferation signaling pathways. Using a nude mouse subcutaneous xenograft model, our data also confirmed that in vivo PFDA exposure promotes tumor growth, with significant increases in both tumor volume and weight. In summary, this study lays a solid foundation for further in-depth toxicological research on PFDA.

Authors

Institutions

Publication Details

Journal
International Immunopharmacology
Published
2026-09-13
DOI
https://doi.org/10.1016/j.intimp.2026.117379
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Perfluorodecanoic acid (PFDA) exposure, through stabilizing HIF-1α to induce VEGF/VEGFR2 autocrine signaling, promotes colorectal cancer cell proliferation

Lan Zhang, Sha Liu, Song Lei, Suo Siyuan et al.
International Immunopharmacology
Cancer, Hypoxia, and Metabolism
article

Perfluorodecanoic acid (PFDA) exposure, through stabilizing HIF-1α to induce VEGF/VEGFR2 autocrine signaling, promotes colorectal cancer cell proliferation

Lan Zhang, Sha Liu, Song Lei, Suo Siyuan, Wang ZhiYu, Qin Yan, Li Na, Zhang YuanFang, Hong Dan, Liu Yawei
article en

Abstract

Perfluorodecanoic acid (PFDA) is a persistent organic pollutant widely present in the environment and resistant todegradation. In recent years, due to its extensive use in industrial production and consumer products, PFDA continuously accumulates in organisms and has become a global public health concern. Although epidemiological data suggest a possible association between PFDA and various cancer risks, its specific carcinogenic mechanism, particularly in colorectal cancer development, remains unclear. Therefore, this study aims to investigate the effects of environmentally relevant concentrations of PFDA on the biological behavior of colorectal cancer cells and to elucidate. the underlying molecular mechanisms. In vitro, human colorectal cancer cell lines HCT116 and HT-29 were used as models. Our results demonstrated that PFDA treatment significantly enhanced the malignant phenotype of cancer cells in a dose-dependent manner. Colony formation ability was enhanced. Meanwhile, cell invasion capacity was also significantly improved. Additionally, PFDA exposure induced glycolytic metabolic reprogramming in cancer cells, a metabolic feature closely associated with rapid tumor growth and malignant progression. To further elucidate the mechanism, our team conducted in-depth molecular biological investigations. The study found that PFDA does not affect gene transcription but instead directly binds to and stabilizes the VHL protein, preventing its degradation of HIF-1α. This consequently significantly upregulates its classic downstream target genes, VEGF and its receptor VEGFR2, thereby activating key downstream pro-survival and proliferation signaling pathways. Using a nude mouse subcutaneous xenograft model, our data also confirmed that in vivo PFDA exposure promotes tumor growth, with significant increases in both tumor volume and weight. In summary, this study lays a solid foundation for further in-depth toxicological research on PFDA.

International ImmunopharmacologyVol. 189
Integrated Chinese Medicine (China) (CN), Chemotherapy Foundation (US), Hebei University of Chinese Medicine (CN), Affiliated Hospital of Hebei University (CN), Hebei University (CN)
Good health and well-being
Openalex Percentile: Top 14%
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.